Led by a former BioNTech executive, Bambusa Therapeutics (BBTX.US) is heading for NASDAQ to fund clinical trials for its eczema drug.
智通财经2026/10/10 06:21Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance
Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.
Earnings Preview | The "buyer strike" in the tech sector is spreading; if Cisco (CSCO.US) guidance falls short of expectations, it could be yet another blow to tech stock sentiment
Cisco will release its financial report on November 12. The market expects EPS to increase by 33% year-on-year and revenue to reach $18.09 billion. The focus will be on AI orders and the integration with Splunk.
Crypto prices
More
